(NASDAQ: NAGE) Niagen Bioscience's forecast annual revenue growth rate of 23.38% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 328.08%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 55.51%.
Niagen Bioscience's revenue in 2025 is $124,709,000.On average, 6 Wall Street analysts forecast NAGE's revenue for 2026 to be $12,472,103,403, with the lowest NAGE revenue forecast at $11,871,961,238, and the highest NAGE revenue forecast at $12,988,449,122. On average, 4 Wall Street analysts forecast NAGE's revenue for 2027 to be $14,961,256,878, with the lowest NAGE revenue forecast at $14,343,557,362, and the highest NAGE revenue forecast at $15,433,709,221.
In 2028, NAGE is forecast to generate $18,020,226,186 in revenue, with the lowest revenue forecast at $17,313,143,795 and the highest revenue forecast at $18,550,138,949.